AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

Methodology

How each market is sized

Each indication's total attributable cost is its US patient population times the extra healthcare cost per patient that the disease causes. Drug spend per patient is shown beside it. Read the caveats before citing a figure; each derivation below names its source.

CaveatsCurrent figuresPer-indication derivationsEvidence grading ↗

Read before citing these numbers

  • Two per-patient figures, each with one definition. Cost per patient is the extra yearly healthcare cost that the disease causes: the medical and pharmacy costs of patients minus those of comparable people without the disease. Drug spend per patient is the mean yearly spend on the drugs that treat the disease, spread across all diagnosed patients, treated or untreated. Use the cost figure to compare one disease with another, and the drug figure to estimate the drug market. No cost figure meets this definition yet for 2 indications: Age-Related Macular Degeneration and Chronic Kidney Disease. No drug-spend figure meets it yet for 24 indications: Acute Myeloid Leukemia, Age-Related Macular Degeneration, Alzheimer's Disease, Asthma, Chronic Hepatitis B, Chronic Kidney Disease, Chronic Obstructive Pulmonary Disease, Crohn's Disease, Diabetic Peripheral Neuropathic Pain, Epilepsy, Heart Failure, HIV, HR+/HER2- Metastatic Breast Cancer, Major Depressive Disorder, MASH / NASH, Migraine, Multiple Myeloma, Non-Small Cell Lung Cancer, Parkinson's Disease, Psoriasis, Schizophrenia, Sickle Cell Disease, Systemic Lupus Erythematosus and Ulcerative Colitis. For acute myeloid leukemia, hospitals bill inpatient chemotherapy inside the stay's DRG, so claims data cannot separate the drug cost.
  • Each figure is a yearly mean in US dollars. When a source reports a monthly cost, the figure is that cost times 12, and the derivation shows the arithmetic. A median, the list price of one drug or a total with no comparison group does not meet the definitions above, so such figures are left out and the cell says "Not yet sourced".
  • Population figures are all-severity prevalence. Every population figure on this page counts all diagnosed patients regardless of severity, because severity-specific US prevalence figures are rarely publicly verifiable. The true addressable market for advanced therapy in any indication is smaller than the headline figure: mild disease is typically not treated with advanced or biologic drugs. Indication-specific detail lives with each derivation below.
  • Source vintages vary by indication, and nothing is inflation-adjusted. Each derivation below states its own data years and dollar year. No figure is adjusted to current dollars, so older cost inputs understate today's prices.
  • This is a top-line market-sizing estimate, not a revenue forecast for any single drug. It does not account for market share, payer mix, line-of-therapy positioning, or list-vs-net pricing beyond what is noted above.

Current figures

"Total attributable cost" is the population times the attributable cost per patient: the extra hospital, clinic, procedure and drug costs that the disease causes. "Drug spend / patient" uses the same population and counts only the drugs that treat the disease.

IndicationPopulation (US)Attributable cost / patientDrug spend / patientTotal attributable cost
Hypertension125.90M$2,759$274$347.4B
Type 2 Diabetes27.00M$12,022$4,670$324.6B
Alzheimer's Disease7.40M$28,078Not yet sourced$207.8B
Obesity107.00M$1,861$198$199.1B
Major Depressive Disorder19.80M$6,429Not yet sourced$127.3B
Asthma24.90M$4,333Not yet sourced$107.9B
Migraine15.93M$6,575Not yet sourced$104.7B
Diabetic Peripheral Neuropathic Pain6.09M$16,588Not yet sourced$101.0B
Atopic Dermatitis19.84M$4,979$1,168$98.8B
Atherosclerotic Cardiovascular Disease19.90M$3,494$1,139$69.5B
Multiple Sclerosis1.00M$65,612$35,154$65.6B
Chronic Obstructive Pulmonary Disease14.20M$4,322Not yet sourced$61.4B
HIV1.10M$44,569Not yet sourced$49.2B
Schizophrenia3.07M$15,957Not yet sourced$49.0B
MASH / NASH14.90M$2,150Not yet sourced$32.0B
Psoriasis7.90M$3,592Not yet sourced$28.4B
Heart Failure7.70M$3,594Not yet sourced$27.7B
Parkinson's Disease1.04M$24,439Not yet sourced$25.4B
Psoriatic Arthritis0.91M$22,272$14,174$20.3B
Chronic Hepatitis B1.70M$11,773Not yet sourced$20.0B
Crohn's Disease1.01M$17,463Not yet sourced$17.7B
Epilepsy3.40M$4,580Not yet sourced$15.6B
Ulcerative Colitis1.25M$11,029Not yet sourced$13.8B
Rheumatoid Arthritis1.36M$9,662$3,331$13.1B
Non-Small Cell Lung Cancer0.18M$70,896Not yet sourced$12.5B
Multiple Myeloma0.20M$54,968Not yet sourced$11.1B
Idiopathic Pulmonary Fibrosis0.16M$41,652$21,067$6.5B
Acute Myeloid Leukemia0.02M$199,362Not yet sourced$4.5B
Sickle Cell Disease0.10M$34,477Not yet sourced$3.4B
HR+/HER2- Metastatic Breast Cancer0.11M$24,600Not yet sourced$2.6B
Systemic Lupus Erythematosus0.20M$8,920Not yet sourced$1.8B
Chronic Kidney Disease37.00MNot yet sourcedNot yet sourcedNot yet sourced
Age-Related Macular Degeneration19.83MNot yet sourcedNot yet sourcedNot yet sourced

373 more indications are tracked. Their population and cost figures are not yet sourced.

Therapeutic areaNot yet sourced
Cardiovascular & Metabolic (26)Cardiogenic Shock in Acute Heart Failure, Congenital Adrenal Hyperplasia, Critical Limb Ischemia, Cushing's Syndrome, Dyslipidemia, Familial Chylomicronemia Syndrome, Growth Hormone Deficiency, Heart Failure with Preserved Ejection Fraction, Heart Failure with Reduced Ejection Fraction, Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypertriglyceridemia, Hypertrophic Cardiomyopathy, Hypogonadism, Hypoparathyroidism, Hypoplastic Left Heart Syndrome, Hypothalamic Obesity, Ischemic Heart Failure, Mixed Hyperlipidemia, Post-Bariatric Hypoglycemia, Resistant Hypertension with Adducin/Ouabain Polymorphisms, Severe Hypertriglyceridemia, Severe Hypoglycemia, Type 1 Diabetes, Vascular Trauma, Venous Thromboembolism
Dermatology (11)Alopecia Areata, Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Cutaneous Lupus Erythematosus, Cutaneous Sarcoidosis, Hidradenitis Suppurativa, Lichen Planopilaris, Necrobiosis Lipoidica, Prurigo Nodularis, Seborrheic Dermatitis, Vitiligo
Gastroenterology & Hepatology (15)Acetaminophen Overdose, Acute-on-Chronic Liver Failure, Alagille Syndrome, Celiac Disease, Eosinophilic Esophagitis, Fibrostenosing Crohn's Disease, Gastroparesis, HIV-Associated Diarrhea, Irritable Bowel Syndrome, Irritable Bowel Syndrome with Constipation, NASH Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Short Bowel Syndrome, Travelers' Diarrhea
Hematology (13)Bacterial Infections in Allogeneic Stem Cell Transplant, Chemotherapy-Induced Thrombocytopenia, Chronic Graft-versus-Host Disease, Graft-versus-Host Disease, Hemophilia A and B, Hemophilia B, Immune Thrombocytopenia, Iron Deficiency Anemia, Paroxysmal Nocturnal Hemoglobinuria, Pyruvate Kinase Deficiency, Severe Sickle Cell Disease, Thrombotic Microangiopathy, Transfusion-Dependent Beta Thalassemia
Immunology (16)Anaphylaxis, Cartilage Defects of the Knee, Dermatomyositis, Eosinophilic Granulomatosis with Polyangiitis, Gout, Graves' Disease, Idiopathic Inflammatory Myopathies, Kidney Transplant Rejection Prophylaxis, Non-Radiographic Axial Spondyloarthritis, Osteoarthritis, Osteoporosis, Severe Refractory Gout, Sjögren's Disease, Systemic Juvenile Idiopathic Arthritis, Systemic Sclerosis, Systemic Sclerosis-Associated Interstitial Lung Disease
Infectious Disease (24)Anthrax, Chlamydia Infection, Chronic Hepatitis Delta, Clostridioides difficile Infection, Complicated Urinary Tract Infection, COVID-19, Cryptococcal Meningitis, Genital Herpes, Gram-Negative Bacterial Infections, Group A Streptococcal Infection, Group B Streptococcus Infection, Helicobacter pylori Infection, Human Metapneumovirus Infection, Invasive Candidiasis, Molluscum Contagiosum, Oral Warts in HIV Patients, Rabies Prevention and Post-Exposure Prophylaxis, Recurrent Clostridioides Difficile Infection, Recurrent Respiratory Papillomatosis, Respiratory Syncytial Virus Infection, Salmonella Infections, Smallpox and Mpox, Staphylococcus aureus Infection, Urinary Tract Infection
Nephrology (11)APOL1-Mediated Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Complement-Mediated Renal Disease, Focal Segmental Glomerulosclerosis, Hemodialysis Access, Hyperphosphatemia, IgA Nephropathy, Kidney Transplant Rejection, Lupus Nephritis, Primary Membranous Nephropathy, Secondary Hyperparathyroidism
Neurology (43)Absence Seizures, Acute Ischemic Stroke, Acute Pain, Alexander Disease, Alzheimer's Disease Agitation, Amyotrophic Lateral Sclerosis, Cerebral Cavernous Malformation, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Low Back Pain, Chronic Pain, Contrast-Enhanced MRI, Dementia with Lewy Bodies, Developmental and Epileptic Encephalopathies, Diabetic Peripheral Neuropathy, Dravet Syndrome, Early Alzheimer's Disease, Essential Tremor, Fibromyalgia, Focal Onset Seizures, Friedreich Ataxia, Frontotemporal Dementia, Generalized Myasthenia Gravis, Guillain-Barré Syndrome, Huntington's Disease, Huntington's Disease Chorea, Idiopathic Hypersomnia, Lennox-Gastaut Syndrome, Multiple Sclerosis Exacerbations, Myasthenia Gravis, Narcolepsy, Neurogenic Orthostatic Hypotension, Neuromuscular Blockade During General Anesthesia, Non-24-Hour Sleep-Wake Disorder, Peripheral Neuropathic Pain, Postoperative Nausea and Vomiting, Primary Generalized Tonic-Clonic Seizures, Secondary Progressive Multiple Sclerosis, Sedation of Mechanically Ventilated ICU Patients, Spinal Muscular Atrophy, Spinocerebellar Ataxia, Spinocerebellar Ataxia Type 2, Subarachnoid Hemorrhage, Tardive Dyskinesia
Oncology (98)Acute Lymphoblastic Leukemia, Advanced Colorectal Cancer, Advanced Gastrointestinal Neuroendocrine Tumors, Advanced Metastatic Colorectal Cancer, Advanced Nectin-4 Expressing Solid Tumors, Advanced ROR1-Expressing Solid Tumors and Lymphomas, Advanced SMARCA4-Deficient Non-Small Cell Lung Cancer, Advanced Solid Tumors, Advanced Solid Tumors and Non-Hodgkin Lymphoma, ALK-Positive Non-Small Cell Lung Cancer, Anemia of Myelofibrosis, Autologous Stem Cell Conditioning in Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Biliary Tract Cancer, Bladder Cancer, Bone Metastases from Solid Tumors, Brain Metastases, Breast Cancer, Cancer Cachexia, Cervical Cancer, Chemotherapy-Induced Nausea and Vomiting, Cholangiocarcinoma, Cholangiocarcinoma with KRAS Mutation, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myeloid Leukemia with T315I Mutation, Classical Hodgkin Lymphoma, Clear Cell Renal Cell Carcinoma, Colorectal Cancer, Conventional Chondrosarcoma, Cutaneous Melanoma, Cutaneous T-Cell Lymphoma, Desmoid Tumors, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Esophageal Squamous Cell Carcinoma, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Gastroenteropancreatic Neuroendocrine Tumors, Gastrointestinal Stromal Tumor, Glioblastoma, Glioma, Head and Neck Squamous Cell Carcinoma, Hematologic Malignancies, Hepatocellular Carcinoma, HER2-Mutant Non-Small Cell Lung Cancer, HER2-Positive Advanced Solid Tumors, HER2-Positive Breast Cancer, High-Grade B-Cell Lymphoma, Higher-Risk Myelodysplastic Syndromes, HPV-Associated Oropharyngeal Cancer, Large B-Cell Lymphoma, Locally Advanced Cutaneous Melanoma, Malignant Brain Tumors, Mantle Cell Lymphoma, Melanoma, Meningioma, Merkel Cell Carcinoma, Metastatic Castration-Resistant Prostate Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndromes, Myelofibrosis, Myxoid/Round Cell Liposarcoma, Nasopharyngeal Carcinoma, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Muscle Invasive Bladder Cancer, Non-Small Cell Lung Cancer with EGFR Mutations, Non-Small Cell Lung Cancer with MET Exon 14 Skipping, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral T-Cell Lymphoma, Polycythemia Vera, Primary Central Nervous System Lymphoma, Prostate Cancer, Rectal Cancer, Recurrent Glioblastoma, Recurrent Glioblastoma with EGFR Alterations, Relapsed/Refractory Acute Myeloid Leukemia, Relapsed/Refractory B-Cell Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia, Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Relapsed/Refractory Lymphoma and AML, Relapsed/Refractory Non-Hodgkin Lymphoma, Renal Cell Carcinoma, ROS1-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumors, Squamous Cell Carcinoma of the Anal Canal, Synovial Sarcoma, Systemic Mastocytosis, Unresectable or Metastatic Uveal Melanoma, Urothelial Carcinoma, Uveal Melanoma, Waldenstrom's Macroglobulinemia
Ophthalmology (11)Allergic Conjunctivitis, Autosomal Dominant Optic Atrophy, Diabetic Macular Edema, Dry Eye Disease, Geographic Atrophy, Leber Congenital Amaurosis, Non-Infectious Uveitis, Ocular Inflammation and Pain, Ocular Surface Anesthesia, Retinitis Pigmentosa, Wet Age-Related Macular Degeneration
Psychiatry (15)Alzheimer's Disease Psychosis, Attention Deficit Hyperactivity Disorder, Bipolar Depression, Bipolar Disorder, Cocaine Intoxication, Cognitive Impairment Associated with Schizophrenia, Generalized Anxiety Disorder, Opioid and Alcohol Dependence, Opioid Overdose, Opioid Overdose Reversal, Opioid Use Disorder, Parkinson's Disease Psychosis, Post-Traumatic Stress Disorder, Social Anxiety Disorder, Treatment-Resistant Depression
Rare & Genetic Diseases (80)AADC Deficiency, Achondroplasia, Acne Vulgaris, Acute Hepatic Porphyria, AL Amyloidosis, Alcohol Use Disorder, Alpha-1 Antitrypsin Deficiency, ANCA-Associated Vasculitis, Angelman Syndrome, Antibody-Mediated Rejection, Ataxia Telangiectasia, Atrial Fibrillation, Bardet-Biedl Syndrome, Bronchiolitis Obliterans Syndrome, Cat Allergy, Charcot-Marie-Tooth Disease, Chronic Rhinosinusitis with Nasal Polyps, Controlled Ovarian Stimulation, Coronary Artery Disease, Cryptosporidiosis, Cystinosis, Dengue, Diabetic Retinopathy, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Dystrophic Epidermolysis Bullosa, Erythropoietic Protoporphyria, Fabry Disease, Facioscapulohumeral Muscular Dystrophy, Fibrodysplasia Ossificans Progressiva, Food Allergy, Gaucher Disease, Generalized Lipodystrophy, Glaucoma, Glycogen Storage Disease Type Ia, Hereditary Angioedema, Herpes Zoster, HIV Pre-Exposure Prophylaxis, Hypercholesterolemia, Hypochondroplasia, Hypophosphatasia, IgG4-Related Disease, Liver Cirrhosis, Lyme Disease, Malaria, Measles, Mumps, Rubella and Varicella, Microscopic Colitis, Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IIIA, Mucopolysaccharidosis Type IVA, Mucopolysaccharidosis Type VI, Myotonic Dystrophy Type 1, Neuronal Ceroid Lipofuscinosis Type 2, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pandemic Influenza, Phenylketonuria, Pneumococcal Disease, Pompe Disease, Postural Orthostatic Tachycardia Syndrome, Prader-Willi Syndrome, Primary Hyperoxaluria Type 1, Primary Immunodeficiency, Prion Disease, Progressive Supranuclear Palsy, Recurrent Pericarditis, Rett Syndrome, Seasonal Influenza, Still's Disease, Stroke Prevention in Atrial Fibrillation, Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy, Tuberculosis, Uveitic Macular Edema, Varicella, Visceral Leishmaniasis, X-linked Adrenoleukodystrophy, X-Linked Myotubular Myopathy, Yellow Fever
Respiratory (10)Allergic Bronchopulmonary Aspergillosis, Autoimmune Pulmonary Alveolar Proteinosis, Chronic Cough in Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, Persistent Pulmonary Hypertension of the Newborn, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Pulmonary Hypertension Associated with Interstitial Lung Disease, Pulmonary Hypertension due to Left Heart Disease

Per-indication derivations

Each indication has three parts: who the population figure counts, what the cost figure measures, and what the drug-spend figure measures. Each part names its source.

Cardiovascular & Metabolic

Atherosclerotic Cardiovascular Disease

Population: 19,900,000 US patients. US adults aged 20 and older who reported a past diagnosis of coronary heart disease, angina, heart attack or stroke. The estimate is from the 2015-2018 NHANES cycle; the age-standardized prevalence was 7.5%. This definition does not include peripheral artery disease or transient ischemic attack. Source: Zhang X, Chen Z, Fang A, et al., American Journal of Preventive Cardiology, 2024 ↗

Cost: $3,494 per patient. Extra yearly healthcare cost of adults with atherosclerotic cardiovascular disease and no diabetes over adults with neither condition, from a regression-adjusted model on MEPS 2010 to 2013. The paper does not state the dollar year. It leaves out patients who also have diabetes (about 31%), and its definition includes peripheral artery disease. Source: Feldman DI, Valero-Elizondo J, Salami JA, et al. Cardiovascular Endocrinology & Metabolism, 2018 ↗

Drugs: $1,139 per patient. Mean yearly spend on cardiovascular medicines per adult aged 40 and over with atherosclerotic cardiovascular disease, MEPS 2012 to 2013, in 2013 US dollars. Source: Salami JA, Valero-Elizondo J, Ogunmoroti O, et al. J Am Heart Assoc, 2017 ↗

Heart Failure

Population: 7,700,000 US patients. US adults with heart failure, from the American Heart Association's 2026 Statistics Update using 2021 to 2023 data. Source: American Heart Association, 2026 Heart Disease and Stroke Statistics Update, At-a-Glance fact sheet ↗

Cost: $3,594 per patient. Extra yearly healthcare spending linked to a heart failure diagnosis, from a two-part regression on MEPS 2009 to 2018 adjusted for demographics, comorbidities and year, in 2018 US dollars. Source: Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. JACC Heart Failure, 2022 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat heart failure per diagnosed patient. The previous figure was the midpoint of a published range, which is not a mean.

Hypertension

Population: 125,900,000 US patients. US adults with high blood pressure, from the American Heart Association's 2026 Statistics Update using 2021 to 2023 data. Source: American Heart Association, 2026 Heart Disease and Stroke Statistics Update, At-a-Glance fact sheet ↗

Cost: $2,759 per patient. Extra yearly healthcare spending linked to a hypertension diagnosis per adult, from a two-part regression on MEPS 2019 adjusted for demographics, insurance, smoking, cholesterol and comorbidity, in 2019 US dollars. Source: Wang Y, Lee JS, Pollack LM, Kumar A, Honeycutt S, Luo F. Am J Prev Med, 2024 ↗

Drugs: $274 per patient. Mean yearly spend on hypertension medicines per adult who bought them ($368, MEPS 2010), times the share of adults with diagnosed or treated hypertension who obtained antihypertensives (74.5%, MEPS 2021 to 2022). The two inputs are about 12 years apart, and generic prices have fallen in that time. Source: Davis KE. MEPS Statistical Brief #404, AHRQ, April 2013; Hill SC, Fang Z. MEPS Statistical Brief #563, AHRQ, July 2025 ↗

Obesity

Population: 107,000,000 US patients. US adults aged 20 and over with a BMI of 30 or more in 2022. IHME modeled the estimate from measured NHANES data and bias-corrected self-reported survey data. Source: DeCleene NK et al. (IHME), JAMA, 2026 ↗

Cost: $1,861 per patient. Extra yearly medical cost per adult with obesity over the lowest-cost weight group, from a two-part regression on MEPS 2011 to 2016 with self-reported weight corrected against NHANES measurements, in 2019 US dollars. Source: Ward ZJ, Bleich SN, Long MW, Gortmaker SL. PLoS ONE, 2021 ↗

Drugs: $198 per patient. 2025 US net sales of the anti-obesity medicines Zepbound (Eli Lilly, $13,484 million) and Wegovy plus Saxenda (Novo Nordisk, DKK 51,283 million, converted at the Federal Reserve's 2025 average of 6.6137 DKK per US dollar), divided across all US adults with obesity. Off-label use of Mounjaro and Ozempic, compounded GLP-1 drugs and older weight-loss medicines are not counted. Source: Eli Lilly and Company, Form 10-K for FY2025 (filed 2026-02-12) ↗

Type 2 Diabetes

Population: 27,000,000 US patients. US people of all ages with diagnosed type 2 diabetes in 2023. It is CDC's count of everyone with diagnosed diabetes minus its count of people with diagnosed type 1 diabetes. People with undiagnosed diabetes are not counted. Source: CDC, National Diabetes Statistics Report ↗

Cost: $12,022 per patient. Average yearly medical cost attributable to diabetes per person with diagnosed diabetes, from the American Diabetes Association's cost model (attributable cost over the expected cost without diabetes), in 2022 US dollars. It covers all types of diabetes. Source: Parker ED et al. (American Diabetes Association), Diabetes Care, 2024 ↗

Drugs: $4,670 per patient. Mean yearly spend on diabetes medicines per adult who received any diabetes care in the year: $4,870 per adult who bought a diabetes prescription, times the 95.9% of those adults who used one, MEPS 2021 to 2022, in 2022 US dollars (payments before rebates). It covers all types of diabetes and community-dwelling adults only. Source: Berdahl TA, Moriya AS. MEPS Statistical Brief #568, AHRQ, December 2025 ↗

Dermatology

Atopic Dermatitis

Population: 19,841,686 US patients. US adults with atopic dermatitis in 2024, from the National Health Interview Survey. The authors converted the adult prevalence of 7.6% to a national count. Children are not included; the same study estimates 12.7% prevalence in children in 2024. Source: Chan KR, Keddie SH, Flohr C, Tsoi MF, Journal of the American Academy of Dermatology, 2025 (as reported by HealthDay, quoting the authors) ↗

Cost: $4,979 per patient. Extra yearly healthcare cost of adults with atopic dermatitis over controls matched 1:3 on age, sex and region, as reported by the authors, in 2018 US dollars. IBM MarketScan claims for 2018. This unadjusted difference covers all 31,164 adults; the adjusted excess is reported only by subgroup. Source: Manjelievskaia J et al., J Manag Care Spec Pharm, 2021 ↗

Drugs: $1,168 per patient. Mean yearly spend on atopic dermatitis medicines per diagnosed patient, in 2019 US dollars (allowed amounts). Dermatology records linked to IQVIA PharMetrics Plus claims, 2016 to 2018. Only 3.6% of the cohort used a biologic, so the figure predates wide dupilumab use and likely understates current spend. Source: Wang X, Boytsov NN et al., J Manag Care Spec Pharm, 2022 ↗

Psoriasis

Population: 7,900,000 US patients. US adults with a diagnosis of psoriasis, from National Health Interview Survey data. The study found that about 3% of adults had the diagnosis and converted that to a national count. Source: Smith B, Kim YJ, Tung JK, Journal of the American Academy of Dermatology, 2025 (as described by co-author Joe Tung, ReachMD interview) ↗

Cost: $3,592 per patient. Mean yearly healthcare cost of patients with psoriasis and no psoriatic arthritis ($11,062) minus that of matched controls ($7,470), in 2019 US dollars. IBM MarketScan commercial claims, 2009 to 2020. This is a difference of reported means with no further adjustment. Source: Merola JF et al., Clin Rheumatol, 2021 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat psoriasis per diagnosed patient.

Gastroenterology & Hepatology

Crohn's Disease

Population: 1,011,000 US patients. US patients with Crohn's disease of all severities. The source and method are the same as for ulcerative colitis: pooled Medicare, Medicaid and commercial claims, extrapolated to the 2020 census population. Source: Lewis JD et al., Gastroenterology, 2023 ↗

Cost: $17,463 per patient. Extra yearly direct healthcare cost of adults with Crohn's disease over patients with no inflammatory bowel disease, matched 1:5, as reported by the authors. Optum employer claims, 1999 to 2017, commercially insured adults. The abstract does not state the dollar year. Source: Manceur AM et al., J Med Econ, 2020 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat Crohn's disease per diagnosed patient.

MASH / NASH

Population: 14,900,000 US patients. This is the modelled number of US adults with MASH in 2020, from a microsimulation calibrated to NHANES prevalence data from 2001 to 2018 (Le et al., JAMA Network Open, 2025). It is a model output and includes undiagnosed people. The same model projects 23.2 million cases by 2050. Source: Le et al., JAMA Network Open, 2025 ↗

Cost: $2,150 per patient. Extra yearly total cost of Medicare fee-for-service beneficiaries aged 66 and over with diagnosed MASH over beneficiaries without it, after inverse-probability weighting (Parts A, B and D, 2016 to 2022 claims), in 2022 US dollars. It describes diagnosed patients, while the population figure also counts people with no diagnosis. Source: Albarmawi et al., Journal of Medical Economics, 2026 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat MASH per diagnosed patient. Rezdiffra's reported sales are not stated as US-only, and Wegovy's sales for MASH are not reported, so the sales of the drugs that treat it cannot be added up.

Ulcerative Colitis

Population: 1,253,000 US patients. US patients with ulcerative colitis of all severities, from pooled US claims data: Medicare, Medicaid in five states and commercial insurance. The authors standardized prevalence to 2018 US census estimates and applied it to the 2020 census population. Source: Lewis JD et al., Gastroenterology, 2023 ↗

Cost: $11,029 per patient. Extra yearly direct healthcare cost of adults with ulcerative colitis over patients with no inflammatory bowel disease, matched 1:5, as reported by the authors. Optum employer claims, 1999 to 2017, commercially insured adults. The abstract does not state the dollar year. Source: Pilon D et al., Curr Med Res Opin, 2020 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat ulcerative colitis per diagnosed patient.

Hematology

Sickle Cell Disease

Population: 100,000 US patients. This is a model-based estimate for 2008 from two national studies that applied birth-cohort prevalence to US Census data, as cited in CDC surveillance. It is a model output. CDC linked-data surveillance found 9,141 people with sickle cell disease in Georgia in 2018, against an earlier modelled estimate of 5,890. Source: Snyder et al., MMWR Surveillance Summaries 71(9), 2022 ↗

Cost: $34,477 per patient. Average yearly medical cost attributable to sickle cell disease per surviving person, commercially insured people aged 0 to 64 in MarketScan claims 2007 to 2018 against weighted MEPS controls, in 2020 US dollars. Prescription medicines are included. Source: Johnson et al., Blood Advances, 2023 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat sickle cell disease per diagnosed patient.

Immunology

Psoriatic Arthritis

Population: 912,292 US patients. US adults aged 20 and over who reported a diagnosis of psoriatic arthritis in NHANES, January 2017 to March 2020. NHANES samples the noninstitutionalized US population. The diagnosis is self-reported. Source: Poudel D, Dhital R, Karmacharya P, Arthritis & Rheumatology (ACR Convergence 2024 abstract 2312), 2024 ↗

Cost: $22,272 per patient. Mean yearly healthcare cost of patients with psoriatic arthritis ($29,742) minus that of matched controls ($7,470), in 2019 US dollars. IBM MarketScan commercial claims, 2009 to 2020. The authors report one control mean for all of their matched controls, so this is a difference of reported means with no further adjustment. Source: Merola JF et al., Clin Rheumatol, 2021 ↗

Drugs: $14,174 per patient. Mean yearly cost of biologics and conventional DMARDs per patient with psoriatic arthritis, over all diagnosed patients in the cohort, in 2013 US dollars (plan-paid amounts). MarketScan commercial and Medicare supplemental claims, 2010 to 2013. Biologic use has grown since then, so the figure likely understates current spend. Source: Greenberg JD et al., J Rheumatol, 2016 ↗

Rheumatoid Arthritis

Population: 1,360,000 US patients. This is the US adult prevalence of rheumatoid arthritis that Huang et al. (2024) state in their introduction. They take it from global and systematic-review sources (Finckh 2022; Almutairi 2021). The same paper's own MEPS 2018 to 2020 survey weighting gives a much higher count of 4.27 million people with self-reported RA. Source: Huang et al., ACR Open Rheumatology, 2024 ↗

Cost: $9,662 per patient. Extra yearly healthcare cost of Medicare fee-for-service beneficiaries aged 65 and over with rheumatoid arthritis over 1:1 matched controls, adjusted by regression ($16,374 against $6,712), in 2013 US dollars, 2010 to 2013 claims. A national survey estimate (MEPS) exists but counts self-reported cases, about three times the diagnosed population, which dilutes the excess. This claims-based figure describes diagnosed patients, as the population figure does. It covers patients aged 65 and over only. Source: Chen et al., Rheumatology Advances in Practice, 2018 ↗

Drugs: $3,331 per patient. Mean yearly spend on rheumatoid arthritis drugs (biologics and conventional DMARDs, Part D pharmacy plus Part B medical claims) per diagnosed patient, Medicare fee-for-service beneficiaries aged 65 and over, 2010 to 2013, in 2013 US dollars. Biologics were most of this spend. Same study as the cost figure. Source: Chen CI et al., Rheumatol Adv Pract, 2018 ↗

Systemic Lupus Erythematosus

Population: 204,295 US patients. Estimated number of people in the US who met the ACR classification criteria for SLE in 2018. The authors pooled CDC lupus registries with case finding in 2002-2004 or 2007-2009. They applied sex- and race-specific rates to the 2018 Census population. Source: Izmirly PM, et al., Arthritis & Rheumatology, 2021 ↗

Cost: $8,920 per patient. Mean yearly healthcare expenses of adults with lupus ($17,270) minus those of controls matched 1:5 on age, sex and region ($8,350), from MEPS 2016 to 2018, in 2018 US dollars. The survey sample has 154 adults with lupus. The paper does not say whether its healthcare total includes prescriptions; if it does not, the excess is about $11,480. Source: Grabich S et al., Lupus Science & Medicine, 2022 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat lupus per diagnosed patient. The previous figure could not be traced to its cited source, which is about a different disease.

Infectious Disease

Chronic Hepatitis B

Population: 1,700,000 US patients. This is a modelled estimate of people living with hepatitis B virus infection in the United States and Puerto Rico in 2021 (Razavi-Shearer et al., Journal of Viral Hepatitis, 2025). The model applies country-of-birth prevalence to 2018 to 2022 American Community Survey county data. The uncertainty interval runs from 795,000 to 4.1 million. Source: Razavi-Shearer et al., Journal of Viral Hepatitis, 2025 ↗

Cost: $11,773 per patient. Mean yearly all-cause cost of commercially insured patients with chronic hepatitis B and compensated liver disease ($18,619) minus that of matched controls without hepatitis B ($6,846, read from the paper's Figure 4), MarketScan 2004 to 2015, in 2015 US dollars. Patients with cirrhosis complications, liver cancer or a transplant cost several times more and are excluded, so the figure understates the average across all patients. Source: Nguyen et al., Journal of Hepatology 70:24-32, 2019 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat chronic hepatitis B per diagnosed patient. Tenofovir is also used in HIV, so its sales cannot be split.

HIV

Population: 1,103,895 US patients. US persons aged 13 and over diagnosed with HIV by the end of 2023 and alive at the end of 2024, from CDC national surveillance. People with undiagnosed HIV are not counted. In 2024, 77.0% of this group received any HIV medical care. Source: CDC, National HIV Prevention and Care Objectives: 2026 Update, May 2026 ↗

Cost: $44,569 per patient. Mean yearly all-cause cost of adults with HIV on antiretroviral therapy ($53,945) minus that of 1:3 matched controls without HIV ($9,376), IQVIA PharMetrics Plus commercial claims for 2023, in 2022 US dollars. Commercially insured adults under 65 only. Source: Cohen et al., PharmacoEconomics - Open, 2025 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat HIV per diagnosed patient. Sales of the main antiretrovirals include prevention (PrEP), so they cannot be assigned to treatment.

Nephrology

Chronic Kidney Disease

Population: 37,000,000 US patients. US adults aged 18 and over with CKD stages 1 to 4, from NHANES August 2021 to August 2023 lab data. The estimate uses a single urine albumin and serum creatinine measure, and CDC notes it might overestimate CKD. Kidney failure (stage 5) is excluded. Source: CDC, Chronic Kidney Disease in the United States, March 2026 ↗

Cost: No source meets the definition yet. The previous figure came from adults coded with chronic renal failure, a group that includes dialysis patients; applied to all adults with stage 1 to 4 disease it gives about 60 times that study's own national total. Studies that define kidney disease by lab values, as the population figure does, report Medicare medical costs only.

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat chronic kidney disease per diagnosed patient. The previous figure was a median over all Part D drugs.

Neurology

Alzheimer's Disease

Population: 7,400,000 US patients. Americans aged 65 and over living with Alzheimer's dementia in 2026, from the Alzheimer's Association 2026 Facts and Figures report. Source: Alzheimer's Association, 2026 Alzheimer's Disease Facts and Figures ↗

Cost: $28,078 per patient. Yearly formal-care cost attributable to Alzheimer's disease and related dementias, including nursing home care and excluding unpaid family care, from a regression on the Health and Retirement Study 2010 to 2016 (adults aged 70 and over), in 2020 US dollars. It covers all dementias. Source: Nandi et al., NPJ Aging, 2024 (PMC10853249) ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat Alzheimer's disease per diagnosed patient. The previous figure counted all Medicare drug payments.

Diabetic Peripheral Neuropathic Pain

Population: 6,086,400 US patients. This is US people with diagnosed diabetes, from the CDC National Diabetes Statistics Report (2023 data), multiplied by the prevalence of painful diabetic neuropathy by diabetes type. The rates are 21.5% in type 2 and 13.4% in type 1, from a community cohort of 15,692 people with diabetes in north-west England (Abbott et al., Diabetes Care, 2011). All diagnosed diabetes that is not type 1 is counted as type 2, and the UK rates are applied to the US base. Source: Abbott et al., Diabetes Care, 2011; CDC National Diabetes Statistics Report ↗

Cost: $16,588 per patient. Extra yearly cost of people with painful diabetic peripheral neuropathy over people with diabetes and no neuropathy, pooled across the paper's two painful groups by their size: $9,349 for 44,432 people and $20,887 for 74,812 people with severe pain. Optum claims, 2016 to 2020, in 2021 US dollars. The groups were defined by fills of pain medicines, so the figure describes treated patients and likely overstates the average across everyone with the condition. The comparison is a difference of means with no adjustment. Source: Bromberg et al., Endocrine, 2024 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat painful diabetic neuropathy per diagnosed patient.

Epilepsy

Population: 3,400,000 US patients. This is the CDC estimate of US adults and children with active epilepsy in 2015 (Zack and Kobau, MMWR, 2017). It covers about 3 million adults and 470,000 children. Source: Zack and Kobau, MMWR 66(31), 2017 ↗

Cost: $4,580 per patient. Extra yearly healthcare spending of people with epilepsy over matched controls, adjusted by regression, from MEPS 2010 to 2018, in 2019 US dollars (CDC). Costs are trimmed at the 99th percentile. The figure for epilepsy or seizure combined is higher. Source: Moura et al., Epilepsia, 2022 (CDC author manuscript; PMC10969856) ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat epilepsy per diagnosed patient. The previous figure was a median at average wholesale price.

Migraine

Population: 15,930,593 US patients. This is US adults aged 18 and over (Census Bureau, 1 July 2024) times a 1-year migraine prevalence of 11.7% (AMPP study, Lipton et al., Neurology, 2007, ages 12 and over) times 51.0%, the share of the OVERCOME (US) 2018 migraine cohort who consulted a medical professional for migraine in the past year. It sizes the population in care. The three inputs come from different years and samples, and OVERCOME drew on web panels with a 7% participation rate. Source: Lipton et al., Headache 62(2), 2022 (OVERCOME); Lipton et al., Neurology, 2007; US Census Bureau Vintage 2024 ↗

Cost: $6,575 per patient. Extra yearly direct healthcare cost of migraine patients over 1:1 matched patients without migraine, from Truven MarketScan commercial claims, 2008 to 2013, in 2014 US dollars. No later matched US study was found. Source: Bonafede et al., Headache, 2018 (PMID 29446063) ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat migraine per diagnosed patient. A pharmacy-benefit study gives spend per patient who fills migraine drugs, but no source gives the share of diagnosed patients who are treated.

Multiple Sclerosis

Population: 1,000,000 US patients. This is a rounded figure from the VA Multiple Sclerosis Centers of Excellence. The VA attributes it to a 2019 prevalence study. The page gives no point estimate, data year or age range. Source: VA Multiple Sclerosis Centers of Excellence, How Common Is Multiple Sclerosis ↗

Cost: $65,612 per patient. Extra yearly direct medical cost per person with MS over matched controls without MS, from 2017 to 2019 Optum commercial and Medicare claims with the Medicare Current Beneficiary Survey for drugs and long-term care, in 2019 US dollars (Bebo et al., Neurology, 2022). Source: Bebo et al., Neurology, 2022 ↗

Drugs: $35,154 per patient. Mean yearly spend on retail disease-modifying therapies per person with MS, from the same study and dollar year. Infused therapies sit in a separate clinic-administered line that the paper does not split by drug, so this is a lower bound. Source: Bebo et al., Neurology, 2022 ↗

Parkinson's Disease

Population: 1,040,000 US patients. US people with diagnosed Parkinson's disease in 2017. The study combined claims data and national surveys to make the estimate. About 89% of these people were eligible for Medicare. Source: Yang W, Hamilton JL, Kopil C, et al., npj Parkinson's Disease, 2020 ↗

Cost: $24,439 per patient. Extra direct medical cost per person with Parkinson's disease over a comparison group matched on age, sex, race and insurance, from 2016 Optum claims and 2015 Medicare data, in 2017 US dollars. Source: Yang et al., npj Parkinson's Disease, 2020 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat Parkinson's disease per diagnosed patient. The previous figure was the extra spend on all prescriptions.

Oncology

Acute Myeloid Leukemia

Population: 22,720 US patients. Estimated new AML diagnoses in the US in 2026, from the American Cancer Society. This is an incidence count and does not include people diagnosed in earlier years. Source: American Cancer Society, Key Statistics for Acute Myeloid Leukemia (2026 estimates) ↗

Cost: $199,362 per patient. Cancer-attributable cost in the first year after diagnosis (cases minus matched Medicare controls without cancer): medical services $190,305.0 plus oral drugs $9,057.2, SEER-Medicare claims 2007 to 2013, in 2020 US dollars. The population figure counts new diagnoses, so the first-year cost applies. Source: NCI Cancer Trends Progress Report, Financial Burden of Cancer Care (estimates from Mariotto et al., CEBP, 2020) ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat acute myeloid leukemia per diagnosed patient. Hospitals bill inpatient chemotherapy inside the stay's DRG, so claims data cannot separate the drug cost.

HR+/HER2- Metastatic Breast Cancer

Population: 105,673 US patients. This is the projected number of US women living with metastatic breast cancer on 1 January 2025, from a SEER-based back-calculation model (Gallicchio et al., JNCI, 2022), multiplied by a 62.4% HR+/HER2- share. The share comes from a SEER 2010 to 2016 cohort of de novo metastatic disease, as tabulated in a 2023 review. Other series in that review range from 43.7% to 68.5%. Source: Gallicchio et al., JNCI 114(11), 2022; Torrisi et al., Drugs in Context, 2023 ↗

Cost: $24,600 per patient. Yearly cancer-attributable cost of breast cancer that was distant-stage at diagnosis, in the continuing-care phase (cases minus matched Medicare controls without cancer): medical services $22.3K plus oral drugs $2.3K, SEER-Medicare claims 2007 to 2013, in 2019 US dollars. The population figure counts women living with metastatic disease, so the continuing-care cost applies. It covers all subtypes and only patients metastatic at diagnosis, and the claims predate CDK4/6 inhibitors, so it understates current cost by a wide margin. Source: Mariotto et al., Cancer Epidemiology, Biomarkers & Prevention, 2020 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat HR+/HER2- metastatic breast cancer per diagnosed patient. CDK4/6 inhibitor sales now include early breast cancer, so they cannot be assigned to this market.

Multiple Myeloma

Population: 202,793 US patients. Estimated number of people living with myeloma in the US in 2023, from NCI SEER. This is a prevalence count and includes people diagnosed in earlier years. Source: NCI SEER, Cancer Stat Facts: Myeloma ↗

Cost: $54,968 per patient. Yearly cancer-attributable cost in the continuing-care phase (cases minus matched Medicare controls without cancer): medical services $28,524.9 plus oral drugs $26,442.8, SEER-Medicare claims 2007 to 2013, in 2020 US dollars. The population figure counts people living with myeloma, so the continuing-care cost applies. The claims predate daratumumab-based treatment, so the figure likely understates current cost. Source: NCI Cancer Trends Progress Report, Financial Burden of Cancer Care (estimates from Mariotto et al., CEBP, 2020) ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat multiple myeloma per diagnosed patient. The filings of the companies that sell myeloma drugs do not split out the US sales of several of them (including Tecvayli, Talvey, Sarclisa and Ninlaro) or generics, so the total does not cover the market.

Non-Small Cell Lung Cancer

Population: 176,646 US patients. Estimated new NSCLC diagnoses in the US in 2026. It is the American Cancer Society's 2026 estimate of new lung cancer cases multiplied by its NSCLC share of 77%. This is an incidence count and does not include people diagnosed in earlier years. Source: American Cancer Society, Key Statistics for Lung Cancer (2026 estimates) ↗

Cost: $70,896 per patient. Cancer-attributable cost in the first year after diagnosis (cases minus matched Medicare controls without cancer): medical services $67,148.1 plus oral drugs $3,747.8, SEER-Medicare claims 2007 to 2013, in 2020 US dollars. The population figure counts new diagnoses, so the first-year cost applies. Source: NCI Cancer Trends Progress Report, Financial Burden of Cancer Care (estimates from Mariotto et al., CEBP, 2020) ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat non-small cell lung cancer per diagnosed patient. The previous figure covered about 2.8 months of intravenous first-line therapy. The main lung cancer drugs are also used in other cancers, so their sales cannot be split.

Ophthalmology

Age-Related Macular Degeneration

Population: 19,830,000 US patients. US people aged 40 and older living with any form of AMD in 2019, early or late stage. The VEHSS model combined NHANES retinal imaging, Medicare claims and Census population data. Most of the count is early-stage disease: 18.34 million early-stage and 1.49 million late-stage. Source: Rein DB, et al., JAMA Ophthalmology, 2022 ↗

Cost: No source meets the definition yet. No US study compares all patients with AMD against matched people without it; the previous figure was an all-cause total for wet AMD only.

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat AMD per diagnosed patient. Medicare drug spending files count retinal injections for all eye diseases. The previous figure could not be traced to its source.

Psychiatry

Major Depressive Disorder

Population: 19,800,000 US patients. US adults with a past-year major depressive episode in 2019, from the National Survey on Drug Use and Health. The count includes adults who did not seek care or receive a formal diagnosis. Source: Greenberg PE et al., Advances in Therapy, 2023 ↗

Cost: $6,429 per patient. Extra direct healthcare cost (medical and prescription) per adult with major depressive disorder over matched controls, averaged over all adults with the disorder, in 2019 US dollars. Source: Greenberg et al., Advances in Therapy, 2023 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat major depressive disorder per diagnosed patient.

Schizophrenia

Population: 3,070,739 US patients. This is the estimated number of US adults with schizophrenia in 2024 across all settings, including community, institutional, correctional and unhoused settings (Krasa et al., JAMA Psychiatry, 2026). It rests on a past-year prevalence of 1.17% of adults. Source: Krasa et al., JAMA Psychiatry, 2026 ↗

Cost: $15,957 per patient. Extra yearly direct healthcare cost per person with schizophrenia over exact-matched controls (up to 1:3), by payer, weighted to the US population with schizophrenia, as reported by the authors. MarketScan commercial, Medicare supplemental and Medicaid claims, October 2015 to 2019, in 2019 US dollars. Source: Kadakia et al., Journal of Clinical Psychiatry, 2022 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat schizophrenia per diagnosed patient. The previous figure was the extra spend on all prescriptions.

Respiratory

Asthma

Population: 24,900,000 US patients. US children and adults with current asthma in 2021, from the National Health Interview Survey. The count includes 4.7 million children and 20.3 million adults. Source: Pate CA, Zahran HS, Preventing Chronic Disease (CDC), 2024 ↗

Cost: $4,333 per patient. Extra yearly direct medical cost of asthma per person over people without asthma, from a regression on MEPS 2010 to 2017 adjusted for demographics, insurance, smoking and comorbidity, in 2017 US dollars. Source: Song et al., Journal of Asthma and Allergy, 2020 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat asthma per diagnosed patient. MEPS gives spend per person who bought asthma medicines, but no source gives the share of diagnosed people who buy them.

Chronic Obstructive Pulmonary Disease

Population: 14,200,000 US patients. US adults who report that a doctor told them they had COPD, emphysema or chronic bronchitis, from the 2021 Behavioral Risk Factor Surveillance System (CDC, MMWR). The National Health Interview Survey gives a lower prevalence but no published count. Source: Liu et al., MMWR Morb Mortal Wkly Rep 72(46), 2023 (CDC) ↗

Cost: $4,322 per patient. Yearly medical cost attributable to COPD per patient, from a weighted two-part regression on MEPS 2017 to 2018 (adults aged 45 and over with and without COPD), in 2018 US dollars. Source: Shah et al., Applied Health Economics and Health Policy, 2023 ↗

Drugs: No source meets the definition yet: no study reports mean yearly spend on the drugs that treat COPD per diagnosed patient. MEPS gives spend per person who bought COPD medicines, but no source gives the share of diagnosed people who buy them.

Idiopathic Pulmonary Fibrosis

Population: 157,000 US patients. This is an age- and sex-adjusted prevalence of 46.2 per 100,000 from Optum Clinformatics claims, 2017 to 2022, with a two-claim case definition (Fan et al., Annals of the American Thoracic Society, 2026), applied to the Census Bureau's 1 July 2024 resident population. Adjusted prevalence ranged from 34.4 to 67.1 per 100,000 across the study's primary case definitions. Source: Fan et al., Annals of the American Thoracic Society 23(2), 2026; US Census Bureau Vintage 2024 ↗

Cost: $41,652 per patient. Extra monthly cost of patients with idiopathic pulmonary fibrosis over 4:1 matched controls ($4,667 against $1,196), times 12, Optum commercial and Medicare Advantage claims 2016 to 2023, in 2023 US dollars. Source: Yang et al., Journal of Health Economics and Outcomes Research, 2026 ↗

Drugs: $21,067 per patient. Mean yearly antifibrotic drug cost per treated patient ($72,395, pooled across nintedanib and pirfenidone, MarketScan 2014 to 2018, in 2017 US dollars) times the 29.1% of diagnosed patients who received an antifibrotic (Optum, 2016 to 2023). The inputs come from two studies, and the cost predates generic pirfenidone, so the figure likely overstates current spend. Source: Corral et al., BMC Pulmonary Medicine, 2020 (cost per treated); Yang et al., JHEOR, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC13238604/ (treated share) ↗

← Methodology